Clinical trials: Renal Cell Cancer
Neoplastic Disease, Solid Tumor
Indocyanine Green (ICG) Guided Tumor Resection
This is a study to assess the ability of Indocyanine Green (ICG) to identify neoplastic disease. For many pediatric solid tumors, complete resection of the primary site and/or metastatic deposits is critical for achieving a cure.
- Trial name
- NCT04084067
- Testing
- Indocyanine Green
- Where
- United States
- Volunteers
- 215 people
- Sponsor
- St. Jude Children's Research Hospital
Colon Cancer, Lung Cancer
A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors
Background: Fluciclatide is a small cyclic peptide containing the RGD tri-peptide, which preferentially binds with high affinity to alpha(v)beta(3) integrins, which are up-regulated in and may regulate angiogenesis.
- Conditions
- Colon Cancer, Lung Cancer, Cervical Cancer, Renal Cell Carcinoma
- Trial name
- NCT01176500
- Testing
- (18)Fluciclatide
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Kidney Cancer
DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE
RATIONALE: Studying samples of blood and/or tissue in the laboratory from patients with kidney cancer receiving sorafenib may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00900536
- Testing
- mutation analysis, polymorphism analysis, protein expression analysis
- Where
- United Kingdom
- Sponsor
- Medical Research Council
Advanced Cancer, Advanced Malignancies
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
- Conditions
- Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer
- Trial name
- ARC-25 (NCT05891171)
- Testing
- AB598, Zimberelimab, Fluorouracil
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Arcus Biosciences, Inc.
HLRCC, Sporadic Papillary Renal Cell Cancer
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Background: At the present time, there are no drugs that have been proven to work in patients with papillary kidney cancer that has spread (metastasized) beyond the kidneys.
- Trial name
- NCT01130519
- Testing
- Bevacizumab, Erlotinib
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma
Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and Comparison of Imaging Techniques
Prospective observational study to assess bone predictive biomarkers for TKI response in RCC patients with bone metastasis and HRQoL with TKI in these patients as well as the sensitivity and specificity of whole body magnetic…
- Trial name
- METHEOS (NCT02747173)
- Where
- 12 sites in Spain
- Volunteers
- 4 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Urothelial Carcinoma, Kidney Cancer
Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases
This is a phase 2 study of the drug denosumab for the management bone metastases from urothelial cancer. The purpose of this study is to find out how effective denosumab is in the management of bone metastases from urothelial…
- Conditions
- Urothelial Carcinoma, Kidney Cancer, Ureter Cancer, Bladder Cancer
- Trial name
- NCT03520231
- Testing
- Denosumab, Gemcitabine, Carboplatin
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- University Health Network, Toronto
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer
Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer
This phase II trial is studying how well tandutinib works in treating patients who have undergone surgery for metastatic kidney cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
- Trial name
- NCT00408902
- Testing
- tandutinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03228667
- Testing
- N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab
- Where
- 35 sites in United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Lupus Nephritis, Systemic Lupus Erythematosus
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus
The purpose of the study is to evaluate the safety and preliminary efficacy of ATA3219 for treatment of participants with lupus nephritis (LN) following lymphodepletion (LD) and in participants with extrarenal systemic lupus…
- Trial name
- NCT06429800
- Testing
- ATA3219
- Where
- United States
- Sponsor
- Atara Biotherapeutics
Kidney Neoplasms, Metastatic Renal Cell Cancer
Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma
Patients who are candidates for first line treatment with Sunitinib 50mg 4/6 regimen in accordance with the Marketing Authorisation who meet the inclusion/exclusion criteria will be offered participation in this study during the…
- Trial name
- SURF (NCT02689167)
- Testing
- Sunitinib
- Where
- France
- Volunteers
- 226 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Metastatic Renal Cell Carcinoma, Advanced Refractory Solid Tumors Histologically or Cytologically Confirmed
Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors
This is an open-label, multicenter dose-escalation phase I study using a 3+3+3 design (i.e., 3 to 9 patients per dose level) in patients with mRCC or others advanced refractory solid tumors.
- Trial name
- PARASOL (NCT01202032)
- Testing
- Association of Bevacizumab (BVC)+ Pazopanib (PZP)
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Centre Leon Berard
Renal Cell Carcinoma
Robotic-assisted vs. Open Partial Nephrectomy
ROBOCOP is an open-label, randomized controlled feasibility trial comparing robotic-assisted and open partial nephrectomy in preparation for a confirmative phase III randomized controlled trial.
- Trial name
- ROBOCOP (NCT04534998)
- Testing
- Partial nephrectomy
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Universitätsmedizin Mannheim
Advanced Non-Clear Cell Kidney Cancer
Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
This research study is studying the combination of Atezolizumab and Bevacizumab as a possible treatment for Advanced Non-Clear Cell Kidney Cancer.
- Trial name
- NCT02724878
- Testing
- Bevacizumab, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Dana-Farber Cancer Institute
Renal Cell Carcinoma
Evaluation of the Efficacy of Radiofrequency in the Treatment of Renal Tumors
Multi-institutional registry on a cohort of 310 patients with biopsy-proven renal cell carcinoma treated by Radiofrequency ablation.
- Trial name
- RF-REIN (NCT02850809)
- Where
- 8 sites in France
- Volunteers
- 310 people
- Sponsor
- University Hospital, Bordeaux
Childhood Acute Lymphoblastic Leukemia, Childhood Rhabdomyosarcoma
Evaluating Dactinomycin and Vincristine in Young Patients With Cancer
This laboratory study is evaluating how well dactinomycin and vincristine work in treating young patients with cancer. Studying samples of blood and urine in the laboratory from patients with cancer may help doctors learn how…
- Conditions
- Childhood Acute Lymphoblastic Leukemia, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Ewing Sarcoma
- Trial name
- NCT00674193
- Testing
- pharmacological study, laboratory biomarker analysis
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 158 people
- Sponsor
- Children's Oncology Group
Renal Neoplasms, Pathology
Optimising Renal Tumour Management Through Artificial Intelligence Modules
The goal of this observational study is to improve the management of people with renal tumour by multimodal artificial intelligence(AI). It will also measure the accuracy of the predictions from AI models.
- Conditions
- Renal Neoplasms, Pathology, Renal Cell Cancer
- Trial name
- NCT06714916
- Where
- China
- Volunteers
- 2,100 people
- Sponsor
- Shao Pengfei
Carcinoma, Renal Cell
Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
The purpose of this study is to determine the effect of a sunitinib administration schedule 2/1 (2 weeks of treatment followed by 1 week without) compared to a schedule 4/2 (4 weeks of treatment followed by 2 weeks without) on…
- Trial name
- ASSET (NCT03109015)
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Duke University
Metastatic Renal Cell Carcinoma
PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer
The primary objective of the pilot study is to determine activity of PAC-1 and nivolumab combination in subjects with metastatic renal cell carcinoma previously treated with immune checkpoint inhibitor therapy as assessed by…
- Trial name
- NCT03927248
- Testing
- Nivolumab
- Sponsor
- HealthPartners Institute
Neuroendocrine Tumors, Liver Metastases
A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors
By improved kidney dosimetry including biological effective dose and taking into account potential risk factors (especially for kidney toxicity), it might be possible to give an optimal and personalized treatment with…
- Trial name
- ILUMINET (NCT01456078)
- Testing
- 177Lu-DOTA-TATE
- Where
- 2 sites in Sweden
- Volunteers
- 60 people
- Sponsor
- Lund University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.